Beyond Air shares drop 22.83% premarket after selling 85% stake in NeuroNOS subsidiary to XTL Biopharmaceuticals.

Beyond Air (NASDAQ:XAIR) fell 22.83% in premarket trading following the announcement that XTL Biopharmaceuticals (NASDAQ:XTLB) acquired 85% of its subsidiary NeuroNOS, which develops nitric oxide-based therapies for autism and neuro-oncology. The transaction, valued at $1 million cash, 19.9% of XTL’s share capital, and up to $32.5 million in milestone payments, may have triggered investor concerns over reduced ownership and potential dilution of Beyond Air’s stake in a high-potential pipeline. While the deal provides upfront capital and aligns with NeuroNOS’s orphan drug designations, the significant premarket decline suggests skepticism about the long-term value of the spinoff or perceived underperformance relative to the subsidiary’s standalone potential. A concurrent $5.0 million private placement, priced at-the-market, may have further pressured sentiment by signaling capital-raising needs amid structural changes.